Advice
in the absence of a submission from the holder of the marketing authorisation:
ibrutinib (Imbruvica®) is not recommended for use within NHS Scotland.
Indication under review: In combination with bendamustine and rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice68KB (PDF)
Medicine details
- Medicine name:
- ibrutinib (Imbruvica)
- SMC ID:
- 1258/17
- Indication:
- In combination with bendamustine and rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 June 2017